CRL

NEUTRALEarnings

Charles River Laboratories Inte

2026-08-25

Price

$297.64

-0.31%

This is the 2026-08-25 snapshot — the signals and analysis for CRL as of this single trading day.

View full CRL research hub →

Score3.2Watchlist

Signals4/8 DNA0/13 Act · 1/4 Risk

SentimentNEUTRALScore: 7

Volume1.1xvs 20d avg

Analysis

CRL is experiencing High-Conviction Price Discovery driven by a recent Q2 earnings beat, a return to organic growth in its DSA segment, and a new vaccine collaboration with Medigen. The stock's PERFECT_STACK and GOLDEN_CROSS technical signals perfectly reflect the aggressive institutional accumulation following a wave of analyst upgrades to the $300-$310 range. Supported by a highly accommodative RISK_ON macro regime, buyers are easily absorbing recent insider sales, validating the stock's status as a market leader.

Fired Signals

ALPHA MALEGOLDEN CROSSMARKET LEADERPERFECT STACKWEAK FINISH

Key Takeaways

Actionable Thesis: Ride the High-Conviction Price Discovery as CRL's Q2 earnings beat and DSA segment recovery attract aggressive institutional buying.
Key Risk: Stretched valuations and a newly filed $10M insider stock sale by a director could introduce near-term supply at the $300 psychological resistance.
What to Watch: Price action around the $300 breakout level to confirm buyers are fully absorbing the insider selling.

← Back to 2026-08-25 View Full CRL History →Yahoo Finance &nearr;